Biolyst › NVCRCash runway
Cash generating
NovoCure Ltd is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Surgical & Medical Instruments & Apparatus.
The next scheduled catalyst is Next quarterly earnings (projected) on December 18, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
NovoCure Ltd generates cash from operations, so a burn-based runway figure does not apply.
Across 6 concluded trials, 67% reached completion rather than being terminated or withdrawn.
Track NVCR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open NVCR in the tracker
Recent history
Date Event Type Phase
October 1, 2026
8-K filed: Reg FD disclosure Filing
—
September 9, 2026
8-K filed: Leadership change Corporate
—
September 1, 2026
8-K filed: Other event Filing
—
July 23, 2026
Quarterly results filed (8-K) Earnings
—
June 30, 2026
8-K filed: Reg FD disclosure Filing
—
June 18, 2026
8-K filed: Reg FD disclosure Filing
—
June 5, 2026
8-K filed: Leadership change Corporate
—
April 30, 2026
Quarterly results filed (8-K) Earnings
—
April 24, 2026
8-K/A filed: Leadership change Corporate
—
April 9, 2026
8-K filed: Leadership change Corporate
—
March 26, 2026
8-K filed: Reg FD disclosure Filing
—
February 26, 2026
Quarterly results filed (8-K) Earnings
—
February 24, 2026
8-K filed: Reg FD disclosure Filing
—
February 23, 2026
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) Trial Milestone
Phase 2
February 11, 2026
8-K filed: Reg FD disclosure Filing
—
February 5, 2026
8-K filed: Reg FD disclosure Filing
—
January 12, 2026
Quarterly results filed (8-K) Earnings
—
December 1, 2025
8-K filed: Leadership change, Reg FD disclosure Corporate
—
October 30, 2025
Quarterly results filed (8-K) Earnings
—
September 15, 2025
8-K filed: Reg FD disclosure Filing
—
August 28, 2025
8-K filed: Reg FD disclosure Filing
—
July 24, 2025
Quarterly results filed (8-K) Earnings
—
June 6, 2025
8-K filed: Leadership change Corporate
—
June 2, 2025
8-K filed: Reg FD disclosure Filing
—
April 24, 2025
Quarterly results filed (8-K) Earnings
—
April 22, 2025
8-K filed: Reg FD disclosure Filing
—
January 10, 2025
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Trial Milestone
Phase 2
November 29, 2024
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). Trial Milestone
Phase 3
September 24, 2024
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) Trial Milestone
Phase 3
June 20, 2023
Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM Trial Milestone
Phase 2
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.